Compare BHK & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHK | KALV |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 687.6M | 551.2M |
| IPO Year | N/A | N/A |
| Metric | BHK | KALV |
|---|---|---|
| Price | $9.65 | $14.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 188.3K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 8.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | ★ $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $204.16 |
| P/E Ratio | $10.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.02 | $7.83 |
| 52 Week High | $11.09 | $19.00 |
| Indicator | BHK | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 56.00 | 43.78 |
| Support Level | $9.60 | $15.77 |
| Resistance Level | $9.69 | $19.00 |
| Average True Range (ATR) | 0.05 | 1.11 |
| MACD | 0.01 | -0.22 |
| Stochastic Oscillator | 71.88 | 3.62 |
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its managed assets in bonds that are investment-grade quality at the time of investment. The trust's investments will include a broad range of bonds, including corporate bonds, U.S. government and agency securities and mortgage-related securities.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.